Fisher & Paykel Healthcare Corporation Limited
FSPKF
Other OTC20.55
USD
- -
- -
ISIN
NZFAPE0001S2
Return %
Stock
S&P500
1Y
-0.72
26.53
3Y
44.62
76.60
5Y
-2.14
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lewis G. Gradon
- Full Time Employees
- 6,978
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 15 Maurice Paykel Place Auckland New Zealand 2013
- IPO Date
- Jul 11, 2001
- Website
- fphcare.com
- Similar Companies
- Business
- Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets innovative medical devices and systems for acute care, respiratory support and the treatment of obstructive sleep apnea. The company offers hospital products including humidification systems, breathing circuits, chambers, masks, nasal cannulas, surgical accessories and interfaces; homecare products such as noninvasive ventilation systems, Optiflow nasal high flow therapy and obstructive sleep apnea masks including the Nova Nasal OSA mask; and specialized solutions for neonatal, infant and surgical care. Fisher & Paykel Healthcare operates globally with key facilities in New Zealand, the United States, Australia, the United Kingdom and Mexico, serving hospitals, homecare providers and medical device manufacturers primarily in North America (46% of revenue), Europe (27%) and Asia Pacific (21%); it maintains headquarters in East Tamaki, Auckland, New Zealand, where it was established in 1969 as part of Fisher & Paykel Industries and separated as a standalone public company listed on the NZX and ASX in 2001. Recent developments include the opening of a third manufacturing facility in Tijuana, Mexico, to enhance production efficiencies and proximity to North American markets; plans for a new facility in Guangzhou, China; strong revenue growth to NZ$1.74 billion in FY24 with underlying net profit after tax up 6% to NZ$264.4 million driven by hospital consumables and OSA mask demand; FY25 guidance projecting revenue of NZ$1.9 billion to NZ$2 billion and net profit of NZ$320 million to NZ$370 million supported by new product introductions like the Airvo 3 system and gross margin expansion to 61.1% through manufacturing improvements and pricing; and H1 FY26 revenue reaching NZ$1.09 billion with 14.6% year-over-year growth and net profit increasing 39%.
Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q4 2026 Earnings Call Transcript
Fisher & Paykel Healthcare (OTCMKTS:FSPKF) Stock Price Down 17.3% – Time to Sell?
Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q2 2026 Earnings Call Transcript
Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q4 2025 Earnings Call Transcript
Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q2 2025 Earnings Call Transcript
Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q4 2024 Earnings Call Transcript
Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q2 2024 Earnings Call Transcript